Predicting Your Risk of Developing Oral Cancer

Heather discovered an oral lesion.
In this video, Heather reveals what happened next.

The Straticyte test is complimentary for a limited time – Click here for more information

Know Your Risk Of Developing Oral Cancer

Late diagnosis of oral cancer is a serious issue that leads to potentially severe outcomes. Currently there is only a 50% survival rate and often those who do survive must cope with disfigurement, pain and the inability to talk or eat normally. We believe we can do better.

Introducing Straticyte. Straticyte is a test that accurately predicts a patient’s risk of developing oral cancer. Straticyte identifies precancerous lesions allowing you and your healthcare professional an opportunity to change the outcome.

And right now Straticyte is being offered complimentary for a limited time.

Ask your healthcare professional for more information about the Straticyte test.

Oral Cancer Statistics
  • 70% of oral cancers are diagnosed at late stage
  • 50% survival rate after five years
  • Kills one person per hour in North America
  • Survivors often have a poor quality of life including disfigurement and the inability to eat or drink normally
Risk factors
  • Tobacco
  • Abuse of alcohol
  • Betel quid and areca nut
  • HPV
  • previous cancer
  • Family history of squamous cell carcinoma (SCC)
  • Sun exposure
Signs and Symptoms
  • white patches, red patches or mixed red and white patches on the lips or in the mouth
  • an ulcer or sore in the mouth or on the lip that doesn’t heal
  • a lump or growth on the lip or in the mouth, including on the tongue
  • thickening in the cheek
  • bleeding in the mouth
  • pain in the mouth that doesn’t go away
  • persistent earache
  • loose teeth
  • dentures that no longer fit
  • slurred speech
  • swollen salivary glands
  • swollen lymph nodes in the neck
  • numbness or loss of sensation over the tongue or lips swelling of the jaw

“Straticyte has the potential to significantly change outcomes for patients by providing more relevant information about dysplastic oral lesions. Currently, there is a gap in predictive tools for healthcare professionals.”

Dr. Anthony B. Morlandt

DDS, MD, Assistant Professor, Chief of the Section of Oral Oncology, Department of Oral and Maxillofacial Surgery, University of Alabama at Birmingham

“Oral Maxillofacial, ENT Surgeons and Oral Pathologists have confirmed a gap in diagnosis and are searching for something that will improve their patient’s outcomes. They see the devastation that happens with a late diagnosis of oral cancer. They want and need new technology that predicts a patient’s progression to oral cancer.”

Dr. David Mock

DDS, PhD, FRDC(C), Professor Oral Pathology/Oral Medicine, former Dean, Faculty of Dentistry, University of Toronto

Straticyte Process:

Straticyte is the only predictor that can distinguish, with high accuracy, oral lesions at high risk of becoming cancerous from those with low or no risk. Straticyte sensitivity is up to 95% and specificity is up to 85%.*

*Hwang JT et al. Individualized five-year risk assessment for oral premalignant lesion progression to cancer. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;123:374–81. doi: https://dx.doi.org/10.1016/j.oooo.2016.11.004